As the global economy recovers in 2021 and the supply of the industrial chain improves, the Human Injection Flu Vaccine market will undergo major changes. According to the latest research, the market size of the Human Injection Flu Vaccine industry in 2021 will increase by USD million compared to 2020, with a growth rate of %.
The global Human Injection Flu Vaccine industry report provides top-notch qualitative and quantitative information including: Market size (2017-2021 value and 2022 forecast). The report also contains descriptions of key players, including key financial indicators and market competitive pressure analysis.
The report also assesses key opportunities in the market and outlines the factors that are and will drive the growth of the industry. Taking into account previous growth patterns, growth drivers, and current and future trends, we also forecast the overall growth of the global Human Injection Flu Vaccine market during the next few years. The global Human Injection Flu Vaccine market size will reach USD million in 2028, growing at a CAGR of % during the analysis period.
This report presents a comprehensive overview, market shares, and growth opportunities of Human Injection Flu Vaccine market by product type, application, key manufacturers and key regions and countries.
Segmentation by type: breakdown data from 2017 to 2022, in Section 2.3; and forecast to 2028 in section 12.6
Trivalent Influenza Vaccine
Quadrivalent Influenza Vaccine
Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 12.7.
6 Months to 3 Years
> 3 Years
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the prominent manufacturers in this market, include
Sanofi
CSL
GSK
Viatris
AstraZeneca
Hualan Bio
Changchun Institute of Biological
Sinovac
Jiangsu GDK
KM Biologics
Table of Content
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Human Injection Flu Vaccine Annual Sales 2017-2028
2.1.2 World Current & Future Analysis for Human Injection Flu Vaccine by Geographic Region, 2017, 2022 & 2028
2.1.3 World Current & Future Analysis for Human Injection Flu Vaccine by Country/Region, 2017, 2022 & 2028
2.2 Human Injection Flu Vaccine Segment by Type
2.2.1 Trivalent Influenza Vaccine
2.2.2 Quadrivalent Influenza Vaccine
2.3 Human Injection Flu Vaccine Sales by Type
2.3.1 Global Human Injection Flu Vaccine Sales Market Share by Type (2017-2022)
2.3.2 Global Human Injection Flu Vaccine Revenue and Market Share by Type (2017-2022)
2.3.3 Global Human Injection Flu Vaccine Sale Price by Type (2017-2022)
2.4 Human Injection Flu Vaccine Segment by Application
2.4.1 6 Months to 3 Years
2.4.2 > 3 Years
2.5 Human Injection Flu Vaccine Sales by Application
2.5.1 Global Human Injection Flu Vaccine Sale Market Share by Application (2017-2022)
2.5.2 Global Human Injection Flu Vaccine Revenue and Market Share by Application (2017-2022)
2.5.3 Global Human Injection Flu Vaccine Sale Price by Application (2017-2022)
3 Global Human Injection Flu Vaccine by Company
3.1 Global Human Injection Flu Vaccine Breakdown Data by Company
3.1.1 Global Human Injection Flu Vaccine Annual Sales by Company (2020-2022)
3.1.2 Global Human Injection Flu Vaccine Sales Market Share by Company (2020-2022)
3.2 Global Human Injection Flu Vaccine Annual Revenue by Company (2020-2022)
3.2.1 Global Human Injection Flu Vaccine Revenue by Company (2020-2022)
3.2.2 Global Human Injection Flu Vaccine Revenue Market Share by Company (2020-2022)
3.3 Global Human Injection Flu Vaccine Sale Price by Company
3.4 Key Manufacturers Human Injection Flu Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Human Injection Flu Vaccine Product Location Distribution
3.4.2 Players Human Injection Flu Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Human Injection Flu Vaccine by Geographic Region
4.1 World Historic Human Injection Flu Vaccine Market Size by Geographic Region (2017-2022)
4.1.1 Global Human Injection Flu Vaccine Annual Sales by Geographic Region (2017-2022)
4.1.2 Global Human Injection Flu Vaccine Annual Revenue by Geographic Region
4.2 World Historic Human Injection Flu Vaccine Market Size by Country/Region (2017-2022)
4.2.1 Global Human Injection Flu Vaccine Annual Sales by Country/Region (2017-2022)
4.2.2 Global Human Injection Flu Vaccine Annual Revenue by Country/Region
4.3 Americas Human Injection Flu Vaccine Sales Growth
4.4 APAC Human Injection Flu Vaccine Sales Growth
4.5 Europe Human Injection Flu Vaccine Sales Growth
4.6 Middle East & Africa Human Injection Flu Vaccine Sales Growth
5 Americas
5.1 Americas Human Injection Flu Vaccine Sales by Country
5.1.1 Americas Human Injection Flu Vaccine Sales by Country (2017-2022)
5.1.2 Americas Human Injection Flu Vaccine Revenue by Country (2017-2022)
5.2 Americas Human Injection Flu Vaccine Sales by Type
5.3 Americas Human Injection Flu Vaccine Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Human Injection Flu Vaccine Sales by Region
6.1.1 APAC Human Injection Flu Vaccine Sales by Region (2017-2022)
6.1.2 APAC Human Injection Flu Vaccine Revenue by Region (2017-2022)
6.2 APAC Human Injection Flu Vaccine Sales by Type
6.3 APAC Human Injection Flu Vaccine Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Human Injection Flu Vaccine by Country
7.1.1 Europe Human Injection Flu Vaccine Sales by Country (2017-2022)
7.1.2 Europe Human Injection Flu Vaccine Revenue by Country (2017-2022)
7.2 Europe Human Injection Flu Vaccine Sales by Type
7.3 Europe Human Injection Flu Vaccine Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Human Injection Flu Vaccine by Country
8.1.1 Middle East & Africa Human Injection Flu Vaccine Sales by Country (2017-2022)
8.1.2 Middle East & Africa Human Injection Flu Vaccine Revenue by Country (2017-2022)
8.2 Middle East & Africa Human Injection Flu Vaccine Sales by Type
8.3 Middle East & Africa Human Injection Flu Vaccine Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Human Injection Flu Vaccine
10.3 Manufacturing Process Analysis of Human Injection Flu Vaccine
10.4 Industry Chain Structure of Human Injection Flu Vaccine
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Human Injection Flu Vaccine Distributors
11.3 Human Injection Flu Vaccine Customer
12 World Forecast Review for Human Injection Flu Vaccine by Geographic Region
12.1 Global Human Injection Flu Vaccine Market Size Forecast by Region
12.1.1 Global Human Injection Flu Vaccine Forecast by Region (2023-2028)
12.1.2 Global Human Injection Flu Vaccine Annual Revenue Forecast by Region (2023-2028)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Human Injection Flu Vaccine Forecast by Type
12.7 Global Human Injection Flu Vaccine Forecast by Application
13 Key Players Analysis
13.1 Sanofi
13.1.1 Sanofi Company Information
13.1.2 Sanofi Human Injection Flu Vaccine Product Offered
13.1.3 Sanofi Human Injection Flu Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.1.4 Sanofi Main Business Overview
13.1.5 Sanofi Latest Developments
13.2 CSL
13.2.1 CSL Company Information
13.2.2 CSL Human Injection Flu Vaccine Product Offered
13.2.3 CSL Human Injection Flu Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.2.4 CSL Main Business Overview
13.2.5 CSL Latest Developments
13.3 GSK
13.3.1 GSK Company Information
13.3.2 GSK Human Injection Flu Vaccine Product Offered
13.3.3 GSK Human Injection Flu Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.3.4 GSK Main Business Overview
13.3.5 GSK Latest Developments
13.4 Viatris
13.4.1 Viatris Company Information
13.4.2 Viatris Human Injection Flu Vaccine Product Offered
13.4.3 Viatris Human Injection Flu Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.4.4 Viatris Main Business Overview
13.4.5 Viatris Latest Developments
13.5 AstraZeneca
13.5.1 AstraZeneca Company Information
13.5.2 AstraZeneca Human Injection Flu Vaccine Product Offered
13.5.3 AstraZeneca Human Injection Flu Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.5.4 AstraZeneca Main Business Overview
13.5.5 AstraZeneca Latest Developments
13.6 Hualan Bio
13.6.1 Hualan Bio Company Information
13.6.2 Hualan Bio Human Injection Flu Vaccine Product Offered
13.6.3 Hualan Bio Human Injection Flu Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.6.4 Hualan Bio Main Business Overview
13.6.5 Hualan Bio Latest Developments
13.7 Changchun Institute of Biological
13.7.1 Changchun Institute of Biological Company Information
13.7.2 Changchun Institute of Biological Human Injection Flu Vaccine Product Offered
13.7.3 Changchun Institute of Biological Human Injection Flu Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.7.4 Changchun Institute of Biological Main Business Overview
13.7.5 Changchun Institute of Biological Latest Developments
13.8 Sinovac
13.8.1 Sinovac Company Information
13.8.2 Sinovac Human Injection Flu Vaccine Product Offered
13.8.3 Sinovac Human Injection Flu Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.8.4 Sinovac Main Business Overview
13.8.5 Sinovac Latest Developments
13.9 Jiangsu GDK
13.9.1 Jiangsu GDK Company Information
13.9.2 Jiangsu GDK Human Injection Flu Vaccine Product Offered
13.9.3 Jiangsu GDK Human Injection Flu Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.9.4 Jiangsu GDK Main Business Overview
13.9.5 Jiangsu GDK Latest Developments
13.10 KM Biologics
13.10.1 KM Biologics Company Information
13.10.2 KM Biologics Human Injection Flu Vaccine Product Offered
13.10.3 KM Biologics Human Injection Flu Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.10.4 KM Biologics Main Business Overview
13.10.5 KM Biologics Latest Developments
14 Research Findings and Conclusion
Sanofi
CSL
GSK
Viatris
AstraZeneca
Hualan Bio
Changchun Institute of Biological
Sinovac
Jiangsu GDK
KM Biologics
*If Applicable.